Raymond Brig

Neoadjuvant Talazoparib in Patients With Germline <i>BRCA1/2</i> Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study

Jennifer K. Litton, J. Thaddeus Beck, Jason M. Jones et al. · The Oncologist · 2023 · 39 citations · Full text

Medicine, Oncology, Pharmacology +16

Neoadjuvant talazoparib in patients with germline<i> BRCA1/2</i> (g<i>BRCA1/2</i>) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study.

Jennifer K. Litton, J. Thaddeus Beck, Jason M. Jones et al. · Journal of Clinical Oncology · 2021 · 33 citations

Medicine, Oncology, Pharmacology +15

Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status

Melinda L. Telli, Jennifer K. Litton, J. Thaddeus Beck et al. · Breast Cancer · 2024 · 12 citations · Full text

Medicine, Oncology, Pharmacology +17